rs1057518309 — DSP Arg451Gly

Desmoplakin Arg451Gly — When Cardiac Glue Dissolves Under Stress

Every heartbeat demands that cardiomyocytes — the muscle cells of the heart — transmit enormous mechanical forces across their shared boundaries. This is the job of the desmosome¹¹ desmosome
A specialized cell-cell junction found in tissues under mechanical stress. The cardiac desmosome anchors the cytoskeletal intermediate filaments of adjacent cardiomyocytes through a multi-protein complex at the intercalated disc, and its master scaffold is desmoplakin (DSP) — the only structural component that spans from the desmosome's cytoplasmic plaque to the keratin and desmin filaments inside the cell. When desmoplakin fails, the result is not immediate structural collapse but a slow, cumulative catastrophe: cardiomyocytes detach, die, and are replaced by fatty-fibrous scar tissue that creates an electrical substrate for lethal arrhythmias.

The DSP p.Arg451Gly variant replaces a positively-charged arginine at position 451 with the smallest, most conformationally flexible amino acid — glycine — within the N-terminal globular domain that anchors desmoplakin to plakoglobin and the desmosomal plaque. Unlike truncating DSP mutations (which reduce the total amount of functional desmoplakin through haploinsufficiency), this missense variant produces a full-length protein that is selectively vulnerable to enzymatic degradation. The result is a classified Pathogenic variant²² classified Pathogenic variant
ClinVar VCV000948761, reviewed by Labcorp Genetics, GeneDx, and Ambry Genetics with no conflicts, for arrhythmogenic cardiomyopathy with woolly hair and keratoderma and arrhythmogenic right ventricular dysplasia 8 associated with biventricular arrhythmogenic cardiomyopathy (ACM).

The Mechanism

Ng et al. (JCI Insight 2019)³³ Ng et al. (JCI Insight 2019)
Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation. JCI Insight 4:e128, 2019 identified the p.Arg451Gly substitution in a family with biventricular ACM and established its pathogenic mechanism through molecular modeling and functional assays. Molecular dynamics simulations revealed that the Arg→Gly substitution causes a "significant loss of intramolecular interactions surrounding a putative calpain⁴⁴ calpain
A calcium-activated protease that cleaves proteins at specific recognition sequences. Calpain activity is elevated in stressed cardiomyocytes and normally degrades damaged contractile proteins; excessive calpain activity at the desmosome destabilizes the intercalated disc complex target site" in the DSP N-terminal domain.

The consequence is selective proteolytic vulnerability: calpain degrades the Arg451Gly mutant desmoplakin faster than wild-type protein, reducing the effective desmoplakin concentration at the intercalated disc under conditions of mechanical or calcium stress. Patient-derived induced pluripotent stem cell (iPSC) cardiomyocytes confirmed substantially reduced connexin-43 levels at intercalated discs — reflecting broader intercalated disc remodeling downstream of desmoplakin deficiency — despite normal electrical propagation at baseline. In silico screening by the same team identified three additional ACM desmoplakin mutations (S299R, S442F, S507F) sharing enhanced calpain susceptibility, suggesting this mechanism is a recurrent theme across N-terminal domain missense variants rather than unique to p.Arg451Gly.

The Evidence

The initial identification of DSP p.Arg451Gly was in a family with biventricular ACM with a LOD score of 7.65⁵⁵ family with biventricular ACM with a LOD score of 7.65
LOD (logarithm of the odds) score: a statistical measure of genetic linkage. LOD ≥ 3 is conventionally considered significant; 7.65 is exceptionally strong evidence for co-segregation of the variant with disease in the family, establishing near-certain causality. The variant is absent from gnomAD population databases (1 carrier in 805,808 alleles globally), consistent with strong negative selection against a high-penetrance cardiac disease variant.

The broader DSP cardiomyopathy literature provides robust context for clinical risk. Smith et al. (Circulation 2020)⁶⁶ Smith et al. (Circulation 2020)
Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 141:1872–1884, 2020 studied 107 patients with pathogenic DSP variants and found that left ventricular (LV) predominant disease occurred in 55% (versus 0% for PKP2 mutations; p<0.001), subepicardial late gadolinium enhancement (LGE) on MRI in 40%, and preserved LVEF in 35% of those with imaging-positive fibrosis — establishing that fibrosis precedes and is disproportionate to systolic dysfunction. This is the defining challenge of DSP cardiomyopathy: standard echocardiography misses the fibrotic substrate that underlies most arrhythmic events.

Wang et al. (Europace 2022)⁷⁷ Wang et al. (Europace 2022)
Clinical characteristics and risk stratification of desmoplakin cardiomyopathy. Europace 24:268–277, 2022 followed 91 DSP variant carriers for a median 4.3 years and found sustained ventricular arrhythmia (VA) at 5.9 per 100 person-years and heart failure at 6.7 per 100 person-years. Acute myocardial injury episodes — episodes of chest pain, troponin elevation, and new MRI changes without obstructive coronary disease — affected 22% of participants and were the strongest predictors of subsequent arrhythmia and heart failure.

Gasperetti et al. (Eur Heart J 2025)⁸⁸ Gasperetti et al. (Eur Heart J 2025)
Clinical features and outcomes in carriers of pathogenic desmoplakin variants. Eur Heart J 46:362–376, 2025 enrolled 800 DSP pathogenic variant carriers across 26 institutions. Over 3.7 years, 17.4% developed sustained VA (3.9%/year annual rate) and 9.0% required heart failure hospitalization. Independent VA predictors included female sex (aHR 1.547), prior non-sustained VT (aHR 1.721), prior sustained VA (aHR 1.923), LVEF ≤50% (aHR 1.645), and myocardial injury episodes (HR 2.394). Critically, 32.5% of carriers met no conventional diagnostic criteria for ARVC, DCM, or NDLVC — underscoring that negative standard phenotypic screening cannot exclude genotype-positive DSP cardiomyopathy.

The DSP Risk Score (Carrick et al., Eur Heart J 2024)⁹⁹ DSP Risk Score (Carrick et al., Eur Heart J 2024)
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Eur Heart J 45:2968–2979, 2024 provides a validated five-predictor model (female sex HR 1.9, NSVT history HR 1.7, 24-hour PVC burden, LVEF <50% HR 1.5, moderate-to-severe RV dysfunction HR 6.0) with c-statistic 0.782 in the development cohort and 0.791 on external validation. The score stratifies patients into low (<5%), intermediate (5–20%), and high-risk (>20%) 5-year VA probability categories with 100% negative predictive value in the low-risk group.

Practical Actions

Carrying a pathogenic DSP missense variant changes clinical management fundamentally — not because disease is certain, but because the risk is high enough and the window for prevention wide enough to warrant structured surveillance. The goals are: (1) quantify fibrosis burden before systolic dysfunction develops, (2) identify arrhythmia risk predictors while time permits ICD planning, and (3) protect first-degree relatives through cascade genetic testing.

Cardiac MRI with late gadolinium enhancement is non-negotiable — echocardiography cannot detect the subepicardial fibrosis that is the defining pathological substrate of DSP cardiomyopathy. Ambulatory ECG monitoring (at least 14 days) quantifies PVC burden, a direct DSP Risk Score input. Competitive sport restriction is recommended for confirmed disease, as exercise-associated myocardial stress can trigger "hot phase" episodes that deposit additional fibrosis and elevate downstream arrhythmia risk.

Interactions

DSP p.Arg451Gly shares a pathogenic mechanism — enhanced calpain-mediated N-terminal domain degradation — with at least three other DSP missense variants (S299R, S442F, S507F) identified in the same functional screen. Compound or digenic desmosomal genotypes (DSP plus PKP2, DSG2, or JUP variants) have been reported with more severe biventricular phenotypes and earlier disease onset, though specific DSP Arg451Gly compound data are not published. SCN5A sodium channel variants may modify arrhythmia penetrance as electrophysiological modifiers in desmosomal cardiomyopathy families.